AI faces its moment of truth

Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts or cloud all their efforts.

watch now
Watch the webinar on demand
Anthony Philippakis

Anthony Philippakis

Chief Data Officer; Co-Director of the Eric and Wendy Schmidt Center, Broad Institute of MIT and Harvard

Anthony Philippakis is the chief data officer of the Broad Institute of MIT and Harvard, and the co-director of the Eric and Wendy Schmidt Center

He trained as a cardiologist at Brigham and Women’s Hospital, with a focus on rare genetic cardiovascular diseases. At the Broad Institute he is the founding director of the Data Sciences Platform, an organization of over 200 software engineers and computational biologists that develops software for analyzing genomic and clinical data. In addition to his roles at the Broad Institute and Brigham and Women’s Hospital, Philippakis is a venture partner at GV, focusing on machine learning, distributed computing, and genomics.

Philippakis received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M.Phil) in mathematics at Cambridge University.


Andrew Hopkins

CEO, Exscientia

Andrew is one of the most distinguished and cited scientists in modern drug discovery. As part of his role as founder and CEO of Exscientia, he invented and championed an automated and algorithmic approach to drug design and drug discovery. Prior to that, he spent 14 years at Pfizer and in academia, pioneering cutting-edge projects using data mining and machine learning in the pharmaceutical industry. His papers, published in Nature journals, are widely considered as pivotal points in the new paradigm of modern drug discovery.

Daphne Koller

Daphne Koller

CEO & Founder, Insitro

Daphne Koller is CEO and Founder of insitro, a machine-learning enabled drug discovery company. Daphne is also co-founder of Engageli, was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, the co-CEO and President of Coursera, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 300 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014, and the International Society of Computational Biology in 2017.

Sanjiv Patel

Sanjiv Patel

President & CEO, Relay Therapeutics

Sanjiv Patel brings to Relay Therapeutics more than 20 years of life sciences industry experience. Prior to Relay Therapeutics, Sanjiv was at Allergan for more than a decade, and played a key part in Allergan’s sustained growth and value creation over that period. Sanjiv held roles of increased responsibility, including leading global strategic marketing for all franchises and general management of Allergan’s fastest growth geographic region, the emerging markets. Sanjiv was most recently part of Allergan’s executive team as chief strategy officer, where he was at the center of some of the industry’s largest transactions. His work with the senior leadership team of Allergan defined its long-term objectives and strategy, including divestment and integration planning activities.

Prior to Allergan, Sanjiv was a management consultant at Boston Consulting Group in London and he started his career as a surgeon in the U.K.’s National Health Service.

Sanjiv holds an MBA from INSEAD, MBBS from the University of London and a M.A. in neurosciences from Cambridge University.

Kyle Blankenship

Kyle Blankenship


A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor roles at two daily newspapers in Texas. In addition to a bachelor’s degree from Texas A&M University, Kyle holds a master’s degree in journalism from the University of North Texas in Denton. At Endpoints, Kyle leads the company’s manufacturing coverage as well as running point on virtual events, editing and content strategy. An avid cook and history nerd, you can find Kyle hovering over the stove—spatula in one hand and a World War II tome in the other.